A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia
1. Age ≥ 60 with Acute Lymphoblastic Leukaemia (ALL) OR ≥ 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
2. Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before trial registration)
3. Written informed consent
1. Known HIV infection
2. Blast transformation of CML
3. Mature B-cell leukaemia i.e. Burkitts disease t(8,14)(q24;q32) and variant c-myc translocations e.g. t(2;8)(p12;q24), t(8;22)(q24;q11)
4. Women who are pregnant or lactating
Other trials currently active for Acute Lymphoblastic Leukaemia
A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.
For precursor-B lineage ALL, the main aim is to determine if the addition of Rituximab to standard induction chemotherapy results in improved EFS.
For T lineage ALL, the main aim is to determine if the addition of nelarabine following standard induction therapy improves outcomes.
United Kingdom National Randomised Trial For Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011